IMMX - NASDAQ
Immix Biopharma, Inc.
$8.44
+0.90%Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
At a Glance
Live SnapshotImmix Biopharma, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Immix Biopharma, Inc. Balance Sheet
IMMX • NASDAQ
| Immix Biopharma, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
93.9M | 17.7M | 17.5M | 13.4M | 17.6M | 391.1K | 734K | |
6.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
100.4M | 17.7M | 17.5M | 13.4M | 17.6M | 391.1K | 734K | |
0.0 | 2M | 1.2M | 255.7K | 25.7K | 127.4K | 175.7K | |
0.0 | 2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 1.2M | 255.7K | 25.7K | 127.4K | 175.7K | |
0.0 | 509.2K | 1.1M | 1.1M | 516.2K | 13.7K | 23.5K | |
828.3K | 32.3K | 44.6K | 78.1K | 0.0 | 0.0 | 0.0 | |
101.2M | 20.2M | 19.8M | 14.9M | 18.2M | 532.2K | 933.3K | |
NON-CURRENT ASSETS | |||||||
3.5M | 2.7M | 50.2K | 3.6K | 5.7K | 7.4K | 9.7K | |
114K | 20.4K | 87.2K | 6.7K | 0.0 | 0.0 | 0.0 | |
3.6M | 2.8M | 137.4K | 10.3K | 5.7K | 7.4K | 9.7K | |
104.8M | 22.9M | 19.9M | 14.9M | 18.2M | 539.6K | 942.9K | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
0.0 | 5.4M | 1.4M | 143.1K | 142.9K | 252.3K | 247.5K | |
0.0 | 5.4M | 1.4M | 143.1K | 142.9K | 252.3K | 247.5K | |
0.0 | 2.6M | 2.3M | 1.1M | 9.1K | 342.8K | 241.8K | |
139.3K | 0.0 | 0.0 | 0.0 | 50K | 4.1M | 4.1M | |
0.0 | 65.2K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 342.8K | 0.0 | |
10M | 658.2K | 0.0 | 0.0 | 0.0 | 232.2K | 0.0 | |
10.1M | 8.7M | 3.7M | 1.3M | 202K | 5.3M | 4.6M | |
NON-CURRENT LIABILITIES | |||||||
933.6K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 475K | 0.0 | 0.0 | 0.0 | |
933.6K | 1M | 0.0 | 475K | 0.0 | 0.0 | 0.0 | |
0.0 | 1.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
11M | 9.7M | 3.7M | 1.7M | 202K | 5.3M | 4.6M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | -100K | -100K | -100K | 0.0 | 0.0 | 0.0 | |
5.3K | 2.8K | 2K | 1.4K | 1.3K | 338.0 | 338.0 | |
0.0 | 88.4M | 69.8M | 51.2M | 47.6M | 508.9K | 508.9K | |
-104.5M | -75M | -53.4M | -38M | -29.8M | -5.4M | -4.2M | |
60.2K | -1.1K | 134.7K | 87K | 125.4K | 131.9K | 68.2K | |
198.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
93.8M | 13.3M | 16.4M | 13.2M | 18M | -4.7M | -3.6M | |
93.8M | 13.3M | 16.2M | 13.2M | 18M | -4.7M | -3.6M | |
0.0 | 0.0 | -201.7K | 0.0 | 0.0 | 0.0 | 0.0 | |
SUMMARY | |||||||
104.8M | 22.9M | 19.9M | 14.9M | 18.2M | 539.6K | 942.9K | |
6.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.1M | 1.1M | 0.0 | 0.0 | 50K | 4.1M | 4.1M | |
-92.9M | -16.6M | -17.5M | -13.4M | -17.6M | 3.7M | 3.4M | |
28,806,794 | 28,806,794 | 28,806,794 | 28,806,794 | 28,806,794 | 28,806,794 | 28,806,794 |
SEC Filings
IMMX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | January 09, 2026 | January 09, 2026 |
Related Guides
Continue your IMMX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.